新型抗肿瘤药物所致心脏毒性及分子机制研究进展

侯欢, 林晨, 张敏, 蒋振伟, 陈蓉

中国药学杂志 ›› 2022, Vol. 57 ›› Issue (1) : 8-14.

PDF(967 KB)
中国药学杂志
PDF(967 KB)
中国药学杂志 ›› 2022, Vol. 57 ›› Issue (1) : 8-14. DOI: 10.11669/cpj.2022.01.002
综述

新型抗肿瘤药物所致心脏毒性及分子机制研究进展

  • 侯欢1,2, 林晨1,2, 张敏1,2, 蒋振伟2, 陈蓉1*
作者信息 +

Advances in Study on Novel Anti-Tumor Drugs-Induced Cardiotoxicity and Molecular Mechanisms

  • HOU Huan1,2, LIN Chen1,2, ZHANG Min1,2, JIANG Zhen-wei2, CHEN Rong1*
Author information +
文章历史 +

摘要

肿瘤已经成为人类最大致死原因,发病率与死亡率均呈持续上升趋势。基于目前恶性肿瘤的治疗,传统化疗药物已不能完全满足临床需求。新型抗肿瘤药物靶向特定部位,一定程度上减少了毒副作用,显著改善了肿瘤患者的死亡率和不良预后。然而此类药物所致心血管毒性尤其是心脏毒性已经成为影响患者生存期及预后的一个重要因素,由此引起了越来越多学者的关注。笔者通过归纳分析最新发表文献对新型抗肿瘤药物所致心脏毒性和分子机制的研究进行综述。

Abstract

Cancer has become the world's largest cause of human death, for which the morbidity and mortality are rising. Based on the current treatment regimens of malignant tumors, traditional chemotherapy drugs can not fully meet the clinical needs. Novel anti-tumor drugs targeting specific sites, to a certain extent, reduce toxic and side effects, and significantly improve the mortality and poor prognosis of cancer patients. However, cardiovascular toxicity caused by such drugs, especially cardiotoxicity, has become an important factor affecting the survival and prognosis of patients, thus attracting more and more scholars' attention. This review will highlight recent research of cardiotoxicity caused by novel antitumor drugs and the possible molecular mechanisms.

关键词

新型抗肿瘤药物 / 心脏毒性 / 分子机制

Key words

novel anti-tumor drug / cardiotoxicity / molecular mechanism

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
侯欢, 林晨, 张敏, 蒋振伟, 陈蓉. 新型抗肿瘤药物所致心脏毒性及分子机制研究进展[J]. 中国药学杂志, 2022, 57(1): 8-14 https://doi.org/10.11669/cpj.2022.01.002
HOU Huan, LIN Chen, ZHANG Min, JIANG Zhen-wei, CHEN Rong. Advances in Study on Novel Anti-Tumor Drugs-Induced Cardiotoxicity and Molecular Mechanisms[J]. Chinese Pharmaceutical Journal, 2022, 57(1): 8-14 https://doi.org/10.11669/cpj.2022.01.002
中图分类号： R979.1   

参考文献

[1] LENNEMAN C G, SAWYER D B. Cardio-oncology: An update on cardiotoxicity of cancer-related treatment. Cir Res, 2016, 118(6):1008-1020.
[2] ZAMORANO J L, LANCELLOTTI P, RODRIGUEZ MUÑOZ D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016, 37(36):2768-2801.
[3] MA W, WEI S, ZHANG B, et al. Molecular Mechanisms of Cardiomyocyte Death in Drug-Induced Cardiotoxicity. Front Cell Dev Biol, 2020, 8: 434.
[4] HU Z Q, YU W T, YAO W X, et al. Research progress of cardiotoxicity induced by antitumor drugs and its prevention and treatment measures. J Chin Pharm(中国药房), 2020, 31(2):250-256.
[5] TOCCHETTI C G, CADEDDU C, LISI D D, et al. From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. Antioxid Redox Signal, 2019, 30(18):2110-2153.
[6] NEMETH B T, VARGA Z V, WU W J, et al. Trastuzumab cardiotoxicity: from clinical trials to experimental studies. Br J Pharmacol, 2017, 174(21):3727-3748.
[7] COPELAND-HALPERIN R S, LIU J E, YU A F. Cardiotoxicity of HER2-targeted therapies. Curr Opin Cardiol, 2019, 34(4):451-458.
[8] VERMEULEN Z, SEGERS V F M, KEULENAER G W D. ErbB2 signaling at the crossing between heart failure and cancer. Basic Res Cardiol, 2016, 111(6):1-14.
[9] ROSA G M, GIGLI L, TAGLIASACCHI M I, et al. Update on cardiotoxicity of anti-cancer treatments. Eur J Clin Invest, 2016, 46(3):264-84.
[10] TOTZECK M, MINCU R I, RASSAF T. Cardiovascular adverse events in cancer patients treated with bevacizumab: a meta-analysis of more than 20,000 patients. J Am Heart Assoc, 2017, 6(8):e006278.
[11] HALLER D G, O'CONNELL M J, CARTERIGHT T H, et al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage Ⅲ colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol, 2015, 26(4):715-724.
[12] LAUNAY V V, JANUS N, BEUZEBOC P, et al. Bull Cancer, 2015, 102(11):906-914.
[13] CHOUEIRI T K, MAYER E L, JE Y, et al. Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab. J Clin Oncol, 2011, 29(6):632-638.
[14] DAHLÉN, EDGREN G, LAMBE M, et al. Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study. Ann Intern Med, 2016, 165(3):161-166.
[15] QI W X, SHEN Z, TANG L N, et al. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol, 2014, 78(4):748-762.
[16] CHU T F, RUPNICK M A, KERKELA R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, 2007, 370(9604):2011-2019.
[17] SHAH R R, MORGANROTH J, SHAH D R. Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval). Drug Saf, 2013, 36(5):295-316.
[18] GHIAS A A P, BHAYANI S, GEMMEL D J, et al. Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity. J Community Hosp Intern Med Perspect, 2018, 8(2):87-91.
[19] CORTES J E, JEAN K H, KANTARJIAN H, et al. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol, 2016, 91(6):606-616.
[20] MARTIN H R,SAAVEDRA S C,PERNA C, et al. Cardiac toxicity of immune-checkpoint inhibitors:a clinical case of nivolumabinduced myocarditis and review of the evidence and new chal-lenges. Cancer Manag Res, 2019, 11: 4541-4548.
[21] DIWAKAR J, TAUSEEF A, MITCHEL C, et al. Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment. Ann Transl Med, 2017, 5(17):348.
[22] VARRICCHI G, GALDIERO M R, MARONE G, et al. Cardiotoxicity of immune checkpoint inhibitors. Esmo Open, 2017, 2(4):e000247.
[23] JOHNSON D B, BALKO J M, COMPTON M L, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med, 2016, 375(18):1749-1755.
[24] WANG D Y, SALEM J E, COHEN J V, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA oncol, 2018, 4(12):1721-1728.
[25] MAHMOOD S S, FRADLEY M G, COHEN J V, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol, 2018, 71(16):1755-1764.
[26] MOSLEHI J J, SALEM J E, SOSMAN J A, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet, 2018, 391(10124):933.
[27] SALEM J E, MANOUCHEHRI A, MOEY M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol, 2018, 19(12):1579-1589.
[28] RHEA I B, OLIVEIRA G H. Cardiotoxicity of Novel Targeted Chemotherapeutic Agents. Curr Treat Options Cardiovasc Med, 2018, 20(7):53.
[29] DANHOF S, SCHREDER M, RASCHE L, et al. ‘Real-life' experience of preapproval carfilzomib-based therapy in myeloma-analysis of cardiac toxicity and predisposing factors. Eur J Haematol, 2016, 97(1):25-32.
[30] SCOTT K, HAYDEN P J, WILL A, et al. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev, 2016, 4: CD010816.
[31] GURRAM M K, PULIVARTHI S, EHRESMANN K, et al. Cardiotoxicity associated with bortezomib: A single-center experience. J Cancer Res Ther, 2017, 13(6):961-963.
[32] LAUBACH J P, MOSLEHI J J, FRANCIS S A, et al. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol, 2017, 178(4):547-560.
[33] SIEGEL D, MARTIN T, NOOKA A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica, 2013, 98(11):1753-1761.
[34] ELZARRAD M K, MUKHOPADHYAY P, MOHAN N, et al. Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice. Plos One, 2013, 8(11):e79543.
[35] AN J, SHEIKH M. Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity. Curr Cancer Drug Targets, 2019, 19(5):400-407.
[36] MOHAN N, SHEN Y, ENDO Y, et al. Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes. Mol Cancer Ther, 2016, 15(6):1321-1331.
[37] LISI D D, MADONNA R, ZITO C, et al. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. Int J Cardiol, 2017, 227:11-17.
[38] ZHANG JC, CHEN WD, ALVAREZ JB, et al. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacol Sin(中国药理学报), 2018, 39(11):1693-1698.
[39] VARRICCHI G, GALEIDRO M R, TOCCHETTI C G. Cardiac Toxicity of Immune Checkpoint Inhibitors. Circulation, 2017, 136(21):1989-1992.
[40] LOBENWEIN D, KOCHER F, DOBNER S, et al. Cardiotoxic mechanisms of cancer immunotherapy-A systematic review. Int J Cardiol, 2020, 323:179-187.
[41] TOCCHETTI, CARLO G, GALDIERO, et al. Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors It Is Now Time for Cardio-Immuno-Oncology. J Am Coll Cardiol, 2018, 71(16):1765-1767.
[42] CHEN S C, CORSETTI G, PASINI E, et al. Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity. EBioMedicine, 2017, 21:206-212.
[43] SPUR E M, ALTHOF N, RESPONDEK D, et al. Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes. Toxicology, 2016, 353-354:34-47.
[44] HU X S, DU C Q, YANG L, et al. Proteasome inhibitor MG132 suppresses number and function of endothelial progenitor cells: Involvement of nitric oxide synthase inhibition. Int J Mol Med, 2010, 25(3):385-392.
[45] KONG X T, NGUYEN N T, CHOI Y J, et al. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. Int J Radiat Oncol Biol Phys, 2018, 100(5):1195-1203.
[46] TOTZECK M, MINCU R I, RASSAF T. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients. J Am Heart Assoc, 2017, 6(8):e006278.
[47] CROSS M J, BERRIDGE B R, CLEMENTS P J, et al. Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury. Br J Pharmacol, 2015, 172(4):957-974.
[48] GHERMAN A, CAINAP C, CONSTANTIN A M, et al. Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab. Clujul Med, 2017, 90(4):377-384.
[49] PONDÉ N, AMEYE L, LAMBERTINI M, et al. Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. Eur J Cancer, 2020, 126: 65-73.
[50] SCHLUMBERGER M, TAHARA M, WIRTH L J, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med, 2015, 372(7):621-630.
[51] ORPHANOS G S, IOANNIDIS G N, ARDAVANIS A G. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol, 2009, 48(7):964-970.
[52] GUNNARSSON O, PFANZELTER N R, COHEN R B, et al. Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma. Cancer Manag Res, 2015, 7: 65-73.
[53] CHAAR M, KAMTA J, AIT-OUDHIA S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. Onco Targets Ther, 2018, 11: 6227-6237.
[54] HASINOFF B B, PATEL D. Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib. Cardiovasc Toxicol, 2020, 20(4):380-389.
[55] ZABOROWSKA-SZMIT M, KRZAKOWSKI M, KOWALSKI D M, et al. Cardiovascular complications of systemic therapy in non-small-cell lung cancer. J Clin Med, 2020, 9(5):1268.
[56] PEREZ E A, KOEHLER M, BYRNE J, et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc, 2008, 83(6):679-686.
[57] LIU L, WU J, ZHAO W, et al. Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib: A case report and literature review. Medicine (Baltimore), 2017, 96(21):e6979.
[58] MASUDA N, OHE Y, GEMMA A, et al. Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan. Cancer Sci, 2019, 110(4):1401-1407.
[59] XIA Z Z, LIANG X B, LI C, et al. Clinical application and safety analysis of amlotinib based on real world. Chin J Pharmacoepidemiol(药物流行病学杂志), 2019, 28(7):444-446.
[60] IBAPTISTE F, CAUTELA J, ANCEDY Y, et al. High incidence of atrial fibrillation in patients treated with ibrutinib. Open Heart, 2019, 6(1):e001049.
[61] TOCCHETTI, CARLO G, GALDIERO, et al. Cardiac toxicity in patients treated with immune checkpoint inhibitors it is now time for cardio-immuno-oncology. J Am Coll Cardiol, 2018, 71(16):1765-1767.
[62] CHEN S C, CORSETTI G, PASINI E, et al. Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity. EBioMedicine, 2017, 21: 206-212.
[63] KATSUME Y, ISAWA T, TOI Y, et al. Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: The need for close cardiac monitoring. Intern Med, 2018, 57(21):3157-3162.

基金

国家“重大新药创制”科技重大专项课题项目资助(2017ZX09304021);苏州市科技计划项目资助(SYSD2020101);苏州市卫生青年骨干人才“全国导师制”项目资助(2021年)
PDF(967 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉